LON:BVXP

Bioventix Interim Earnings Results & Report

Bioventix logo
GBX 1,896.55 -53.45 (-2.74%)
As of 11/20/2026 11:53 AM Eastern

Bioventix reported Interim earnings on March 31, 2025. The company reported EPS of GBX 72.27.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

Bioventix EPS Results

Actual EPS
GBX 72.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioventix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioventix Interim Earnings FAQ

Bioventix (LON:BVXP) reported earnings of GBX 72.27 per share for Interim. The report was announced on Monday, March 31, 2025.

Bioventix Earnings Headlines

Bioventix : Posting of Annual Report and Notice of AGM
Elon masterplan could turn $500 into half a million
Jeff Brown called Tesla an AI company in 2018, when Wall Street said it was going bankrupt. The stock has been up as much as 2,433% since. Now Brown says Elon Musk is about to take the final step of his masterplan, and one company is critical to it. Musk has predicted a return of more than 1,000x for early investors. In a free video, Brown shows what Musk is building and names one of his key partners.tc pixel
See More Bioventix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventix and other key companies, straight to your email.

About Bioventix

Bioventix (LON:BVXP) creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

View Bioventix Profile